Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care
BJPsych Open · 2024-09 · 10 (5)
DOI: 10.1192/bjo.2024.727 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 08.08.2024. Verfasst von Denis Agniel und 6 weiteren Autor:innen. Beteiligte Einrichtung: RAND Corporation, Santa Monica, California, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, National Institute of Mental Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Exposure to second-generation antipsychotics (SGAs) carries a risk of type 2 diabetes, but questions remain about the diabetogenic effects of SGAs.
Aims
To assess the diabetes risk associated with two frequently used SGAs.
Method
This was a retrospective cohort study of adults with schizophrenia, bipolar I disorder or severe major depressive disorder (MDD) exposed during 2008–2013 to continuous monotherapy with aripiprazole or olanzapine for up to 24 months, with no pre-period exposure to other antipsychotics. Newly diagnosed type 2 diabetes was quantified with targeted minimum loss-based estimation; risk was summarised as the restricted mean survival time (RMST), the average number of diabetes-free months. Sensitivity analyses were used to evaluate potential confounding by indication.
Results
Aripiprazole-treated patients had fewer diabetes-free months compared with olanzapine-treated patients. RMSTs were longer in olanzapine-treated patients, by 0.25 months [95% CI: 0.14, 0.36], 0.16 months [0.02, 0.31] and 0.22 months [0.01, 0.44] among patients with schizophrenia, bipolar I disorder and severe MDD, respectively. Although some sensitivity analyses suggest a risk of unobserved confounding, E-values indicate that this risk is not severe.
Conclusions
Using robust methods and accounting for exposure duration effects, we found a slightly higher risk of type 2 diabetes associated with aripiprazole compared with olanzapine monotherapy regardless of diagnosis. If this result was subject to unmeasured selection despite our methods, it would suggest clinician success in identifying olanzapine candidates with low diabetes risk. Confirmatory research is needed, but this insight suggests a potentially larger role for olanzapine in the treatment of well-selected patients, particularly for those with schizophrenia, given the drug's effectiveness advantage among them.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RAND Corporation, Santa Monica, California, USA.
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA; and Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA; and Thriving Mind South Florida, Miami, Florida, USA.
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA.
- RAND Corporation, Boston, Massachusetts, USA; and Department of Psychiatry, Cambridge Health Alliance and Harvard Medical School, Cambridge, Massachusetts, USA.
ORCID-Profile: Marcela Horvitz-Lennon
Förderung
- NIMH NIH HHS
- National Institute of Mental Health
Zitieren
APA
Agniel, D., Normand, S. T., Newcomer, J. W., Zelevinsky, K., Poulos, J., Tsuei, J., & Horvitz-Lennon, M. (2024). Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care. BJPsych Open, 10(5). https://doi.org/10.1192/bjo.2024.727
Vancouver
Agniel D, Normand ST, Newcomer JW, Zelevinsky K, Poulos J, Tsuei J, et al. Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care. BJPsych Open. 2024;10(5). doi:10.1192/bjo.2024.727
BibTeX
@article{Agniel2024,
author = {Agniel, Denis and Normand, Sharon-Lise T and Newcomer, John W and Zelevinsky, Katya and Poulos, Jason and Tsuei, Jeannette and Horvitz-Lennon, Marcela},
title = {Revisiting diabetes risk of olanzapine versus aripiprazole in serious mental illness care},
journal = {BJPsych Open},
year = {2024},
volume = {10},
number = {5},
doi = {10.1192/bjo.2024.727}
}
EUVIMED